NEU 3.32% $20.52 neuren pharmaceuticals limited

Ann: Investor Presentation, 14 March 2023, page-14

  1. 2,831 Posts.
    lightbulb Created with Sketch. 592
    Even if Neuren had the NA rights for other indications, it hard to imagine they could do better commercially than the agreement with Acadia.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.